content_image/231868.jpg content_image/231869.jpg content_image/231870.jpg
## Bristol-Myers Squibb 

## Available-For-Sale Securities and Cash Equivalents 

The following table summarizes available-for-sale securities at December 31, 2012 and 2011: 

<img src='content_image/231868.jpg'>

The following table summarizes the classification of available-for-sale securities in the consolidated balance sheet: 

<img src='content_image/231869.jpg'>

Money market funds and other securities aggregating $1,288 million and $5,469 million at December 31, 2012 and 2011, respectively, were included in cash and cash equivalents and valued using Level 2 inputs. Cash and cash equivalents maintained in foreign currencies were $493 million at December 31, 2012 and are subject to currency rate risk. 

At December 31, 2012, $3,512 million of non-current available for sale corporate debt securities and FRS mature within five years. All auction rate securities mature beyond 10 years. 

The change in fair value for the investments in equity and fixed income funds are recognized in other income/expense and are designed to offset the changes in fair value of certain employee retirement benefits. 

The following table summarizes the activity for financial assets utilizing Level 3 fair value measurements: 

<img src='content_image/231870.jpg'>

